Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lomme – page 10

1 744 clinical trials in Lomme, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lomme at a glance
1 744
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 744 trials in Lomme

Open in trial search

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Pituitary tumour benign

Recruiting

Fluoroethyltyrosine F-18 PET Scan for Adults with Suspected Functional Pituitary Adenoma and Unclear MRI Results

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Universitaire De Lille

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-79635322
  • Sponsor:Janssen Cilag International

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Hypereosinophilic syndrome+1

Recruiting

Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Chronic cutaneous lupus erythematosus+2

Recruiting

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Colorectal cancer

Recruiting

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation+1

Recruiting

Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:UZ Leuven

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Lomme

What the registry says about research in the country

01 Rheumatology Research

Clinical trials focusing on rheumatoid arthritis and gout management, including innovative treatment approaches and medication optimization studies.

  • JAK inhibitor dose tapering strategies
  • Combination therapy evaluations
  • Gout flare treatments

Multiple studies are investigating novel therapeutic combinations and treatment optimization approaches for chronic inflammatory conditions.

02 Oncology Studies

Innovative research in prostate cancer diagnostics and lymphoma treatments, with emphasis on advanced imaging and combination therapies.

  • Advanced diagnostic imaging
  • Targeted therapy combinations
  • Bladder cancer treatments

These trials aim to improve cancer detection accuracy and treatment efficacy through innovative approaches.

03 Neurology Research

Studies addressing multiple sclerosis, stroke prevention, and Alzheimer's disease through various therapeutic approaches.

  • Cognitive enhancement trials
  • Stroke prevention strategies
  • MS treatment comparisons

Research focuses on both preventive measures and treatment optimization for neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.